FindTrial
Sign In

NNC0487-0111 B 10141

DRUG10 trials

Sponsors

Novo Nordisk A/S

Conditions

HFpEF or HFmrEF and obesityObesityOverweight or obesityParticipants with overweight or obesityType 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1–3 marketed oral glucose lowering medications.and knee osteoarthritisand obstructive sleep apnoea not treated with positive airway pressureand obstructive sleep apnoea treated with positive airway preassure (PAP)

Phase 3

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)
Not yet recruitingCTIS2024-520443-16-00
Novo Nordisk A/Sand obstructive sleep apnoea treated with positive airway preassure (PAP), Overweight or obesity
Target: 25Updated: 2026-03-24
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)
Not yet recruitingCTIS2024-520442-36-00
Novo Nordisk A/Sand obstructive sleep apnoea not treated with positive airway pressure, Overweight or obesity
Target: 90Updated: 2026-03-31
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)
Not yet recruitingCTIS2024-520444-42-00
Novo Nordisk A/Sand knee osteoarthritis, Overweight or obesity
Target: 70Updated: 2026-04-08
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
Not yet recruitingCTIS2024-520445-23-00
Novo Nordisk A/Sand knee osteoarthritis, Overweight or obesity
Target: 70Updated: 2026-04-08
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
Not yet recruitingCTIS2025-523717-29-00
Novo Nordisk A/SHFpEF or HFmrEF and obesity
Target: 401Updated: 2026-04-17
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
RecruitingCTIS2025-523804-62-00
Novo Nordisk A/SObesity
Target: 235Updated: 2026-04-29
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)
Not yet recruitingCTIS2024-520441-23-00
Novo Nordisk A/Sand type 2 diabetes, Overweight or obesity
Target: 50Updated: 2026-05-04
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
Not yet recruitingCTIS2024-520440-42-00
Novo Nordisk A/SObesity
Target: 210Updated: 2026-05-05
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
Not yet recruitingCTIS2024-520446-31-00
Novo Nordisk A/Sand type 2 diabetes, Participants with overweight or obesity
Target: 85Updated: 2026-05-15
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
WithdrawnCTIS2026-525209-11-00
Novo Nordisk A/SType 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1–3 marketed oral glucose lowering medications.
Target: 110Updated: 2026-09-04